Head to head
10x Genomics vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: TXG · ABT
TXG
10x Genomics
76.10-5.65%
1-year price shape — +556% over the period
Quant Rating A · 100/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| TXG | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 76.10 | 98.73 |
| Change today | -5.65% | +0.58% |
| 1-year return | +556.0% | -24.1% |
| Market cap | $9.92B | $170.84B |
| 52-week range | 11.16 – 102.81 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -128.98 | 31.95 |
| P/E percentile, own 5-yr range | 4th | 62nd |
| P/B | 12.01 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | -0.35 | 3.72 |
| Net profit (TTM) | $-45.60M | $6.44B |
| Revenue (TTM) | $616.91M | $46.59B |
| Revenue growth (YoY) | -12.6% | +13.0% |
| Gross margin | 70.0% | 56.6% |
| Operating margin | -14.9% | 15.8% |
| Net margin | -12.2% | 11.6% |
| Free cash flow (TTM) | $121.44M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 104.2% | 81.2% |
| Insider activity (12mo) | 13 buy / 37 sell | 36 buy / 12 sell |
| Short interest (% of float) | 12.8% | 1.1% |
| Analyst consensus | 55% buy / 45% hold (11) | 100% buy (14) |
| Analyst price target | $65 (-15%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | A (100) | E (15) |
| Company | ||
| Employees | 1,178 | 115,000 |
| Founded | 2012 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.